Published • loading... • Updated
IYN Pharmaceutical Announces Clinical Trials for Macular Degeneration Gene Therapy… “Reduces Injection Requirements by 89%”
Summary by 조선일보
1 Articles
1 Articles
IYN Pharmaceutical announced significant clinical results for ‘NG101,’ a gene therapy for wet age-related macular degeneration (wAMD) being jointly developed with its subsidiary, Elicigen. While existing wAMD patients typically required an average of 10 eye injections per year, patients treated with NG101 maintained their vision with just a single annual dose. IYN Pharmaceutical stated on the 7th that Elicigen (formerly Neuracle Genetics) partic…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right1Center0Last UpdatedBias Distribution100% Right
Bias Distribution
- 100% of the sources lean Right
100% Right
R 100%
Factuality
To view factuality data please Upgrade to Premium
